

www.optumcoding.com

The Essential RBRWS

A comprehensive listing of RBRVS values for CPT® and HCPCS codes



A full suite of resources including the latest code set, mapping products, and expert training to help you make a smooth transition. www.optumcoding.com/ICD10

Contents

Getting Started with The Essential RBRVS	i
Introduction	Introduction–I
Development	
Features	Introduction-1
RBRVS Highlights	Introduction–2
How to Use This Book	Introduction–3
Medicare and RBRVS	Introduction-4
Private Sector Payers and RBRVS	
Capitated Contracts and RBRVS	
Determining a Gross Conversion Factor .	
Determining a Frequency-Adjusted Conversion Factor Developing an RBRVS-Based	Introduction–9
Fee Schedule	Introduction-10
Productivity Analysis Using RBRVS	
Cost/Benefit Analysis	
RBRVS Terminology	
Description of Columns in RBRVS Table	
Modifiers	Introduction-20
Medicare Conversion Factors & GPCIs Co	
GPCI TablesCo	onversion Factors–1
Calculating GPCI Adjusted Reimbursement RateCo	onversion Factors–2
Anesthesia Conversion Factors by LocalityCo	
Anesthesia	
Calculations of Total Anesthesia Values	Anesthesia–iii
Anesthesia Values	Anesthesia–1
Surgery	Surgery–i
Surgery Values	~ .

Appendix A	Radiology	Radiology-
Pathology and Laboratory Values	Radiology Values	Radiology–1
Pathology and Laboratory Values	Pathology and Laboratory	Pathology-i
Medicine Values		
Evaluation and Management	Medicine	Medicine-
Evaluation and Management E/M- Category II Category II Category III Category III Category III Category III Values Category III Category III Values Category IIII Category III Values Category IIII- HCPCS HCPCS Values HCPCS HCPCS - Appendix A Appendix A Appendix A- Description of Columns in Appendix A Appendix A- Appendix B Appendix B Appendix B- OPPS Cap on the Technical Component of Radiology Services Appendix B- 2016 OPPS TC Payment Amount Appendix B- Determining the Lower of the MPFS and OPPS Payment Rates for Diagnostic Radiology Services Appendix B- Multiple Procedure Reduction Appendix B- Table Layout Appendix B-	Medicine Values	Medicine–1
Evaluation and Management E/M- Category II Category II Category III Category III Category III Category III Values Category III Category III Values Category IIII Category III Values Category IIII- HCPCS HCPCS Values HCPCS HCPCS - Appendix A Appendix A Appendix A- Description of Columns in Appendix A Appendix A- Appendix B Appendix B Appendix B- OPPS Cap on the Technical Component of Radiology Services Appendix B- 2016 OPPS TC Payment Amount Appendix B- Determining the Lower of the MPFS and OPPS Payment Rates for Diagnostic Radiology Services Appendix B- Multiple Procedure Reduction Appendix B- Table Layout Appendix B-	Evaluation and Management	E/M-
Category II Values		
Category II Values	Category II	Category II–
Category III Values		
Category III Values	Category III	Category III–
Appendix A		
Appendix A	HCPCS	HCPCS-
Description of Columns in Appendix A		
Description of Columns in Appendix A	Appendix A	Appendix A–I
OPPS Cap on the Technical Component of Radiology Services		
OPPS Cap on the Technical Component of Radiology Services	Appendix B	Appendix B_I
2016 OPPS TC Payment Amount	OPPS Cap on the Technical Component of	
OPPS Payment Rates for Diagnostic Radiology Services	<u></u>	* *
Multiple Procedure ReductionAppendix B- Table LayoutAppendix B-	OPPS Payment Rates for Diagnostic	Appendix R 1
Table LayoutAppendix B-		
· · · · · · · · · · · · · · · · · · ·		
Diagnostic Imaging Family IndicatorAppendix B-	Diagnostic Imaging Family Indicator	Appendix B–3

Introduction

Development

The Essential RBRVS incorporates the relative values produced by the Centers for Medicare and Medicaid Services (CMS) for the Medicare Physician Fee Schedule (MPFS) into a comprehensive reference of resource-based relative value scale (RBRVS) relative values.

Even though RBRVS was developed specifically for assigning reimbursement rates to Medicare services, over 75 percent of non-Medicare payers use Medicare RBRVS to establish fees or maximum allowables for physician services. This works well for those services assigned relative values by CMS for Medicare. However, because Medicare does not assign a value to all services, the MPFS has gaps. In order to create a complete RBRVS-based fee schedule, these gap services need to have relative values assigned.

The Essential RBRVS Gap Methodology

The gaps in *The Essential RBRVS* are created when the Medicare Physician Fee Schedule (MPFS) does not provide values for procedure or supply codes. The gaps are created using various methodologies depending on the code.

For most codes, gap relative values are calculated by using relative value information from the Optum Relative Value Scale and adjusted to a scale similar to the MPFS relative values (RBRVS). The Optum relative values are developed by and are proprietary to Optum. Optum relative values are assigned when Optum has an understanding of how the procedure is typically billed by the industry and how it relates to other procedures. Relative values are based on difficulty, time, work, risk, and resources. Relative values are established by Optum employees, including an Optum Medical Director, clinicians, certified procedural coders, and analysts. Optum also consults with a panel of outside physicians and dentists during the relative value development process for certain codes.

Because Optum relative values are on a different scale than RBRVS relative values, we develop ratios relating the RBRVS and Optum scales for approximately 250 code ranges (within the CPT®, HCPCS, and CDT systems). These ratios are multiplied by the Optum relative value to create the gap value. If Optum does not assign a relative value to a code, a gap value is not calculated. An example of the methodology is as follows (numbers used are for example purposes only): Procedure code 15828 is not valued in the MPFS. Optum has a relative value of 185 for this procedure code. The

calculated ratio of Optum to the MPFS relative value units for the range of codes that this procedure code falls in is .292. The gap value would be $185 \times .292 = 54.02$.

Codes that are valued by Medicare's Clinical Lab Fee Schedule (CLAB); Durable Medical Equipment, Prosthetics/ Orthotics, & Supplies Fee Schedule (DMEPOS); or the Medicare ASP (average sale price) drug pricing files are treated differently. For these codes, the dollar values (national limit in CLAB) are used and relative values are created by dividing the dollar amounts by the MPFS national conversion factor. The CLAB, DMEPOS, and ASP files used are the most recent available at the time of printing. These files may update throughout the year.

Note: Gap relative values should not be used to calculate a Medicare reimbursement rate. In addition, the gap work relative value should not be used to calculate the outpatient prospective payment system (OPPS) rate.

Features

The Essential RBRVS is the most comprehensive resource-based relative value scale available. Here are *The Essential RBRVS* features:

- Physician services, including those not part of the MPFS.
- Clinical laboratory services.
- Level II codes, such as durable medical equipment (DME), medical and surgical supplies, and transportation.
- J codes (injectable drugs).
- Appendix A This table provides the information necessary to determine if Medicare allows or makes adjustments to payment for the following: PC/TC component, assistant-at-surgery, multiple procedures, bilateral procedures, co-surgery or team surgery. The preop, intraop, and postop splits, the endoscopic base code, as well as the indicator identifying the level of physician supervision of diagnostic tests, if any, are also listed in appendix A. The special payment rules for each are identified at the beginning of the table.
- Appendix B Payment for the technical component (TC) portion of a radiology service will be limited to the lesser of the Medicare Physician Fee Schedule (MPFS) amount or the Outpatient Prospective Payment System (OPPS) amount in 2016. This is referred to by CMS as

	Code M	I S	Description	Work Value	Non- Fac PE	Fac PE p	Mal- oractice	Non-Fac Total	Fac Total	Global	Gap OPPS
	65710	A	Keratoplasty (corneal transplant); anterior lamellar	14.45	15.92	15.92	1.07	31.44	31.44	090	
	65730	A	penetrating (except in aphakia or pseudophakia)	16.35	17.29	17.29	1.21	34.85	34.85	090	
	65750	A	penetrating (in aphakia)	16.90	16.89	16.89	1.25	35.04	35.04	090	
	65755	A	penetrating (in pseudophakia)	16.79	16.82	16.82	1.24	34.85	34.85	090	
	65756	A	endothelial	16.84	15.58	15.58	1.25	33.67	33.67	090	
+	65757	С	Backbench preparation of corneal endothelial allograft prior to transplantation (List separately in addition to code for primary procedure)	0.00	0.00	0.00	0.00	0.00	0.00	ZZZ	
	65760	N	Keratomileusis	15.98	13.91	13.91	3.31	33.20	33.20	XXX	
	65765	N	Keratophakia	23.17	20.17	20.17	4.80	48.14	48.14	XXX	
	65767	N	Epikeratoplasty	21.57	18.78	18.78	4.47	44.82	44.82	XXX	
	65770	A	Keratoprosthesis	19.74	18.69	18.69	1.45	39.88	39.88	090	
	65771	N		8.79	7.65	7.65	1.82	18.26	18.26	XXX	
	65772		Corneal relaxing incision for correction of surgically induced astigmatism	5.09	7.32	6.09	0.37	12.78	11.55	090	
	65775		Corneal wedge resection for correction of surgically induced astigmatism	6.91	8.24	8.24	0.50	15.65	15.65	090	
	65778		Placement of amniotic membrane on the ocular surface; without sutures	1.00	39.52	0.60	0.07	40.59	1.67	000	
	65779 65780	A	single layer, sutured Ocular surface reconstruction; amniotic	2.50 7.81	31.41 11.96	1.65	0.18	34.09 20.34	4.33 20.34	000 090	
	0)/00		membrane transplantation, multiple layers	7.01	11.70	11.50	0.57	20.31	20.51	0)0	
	65781	A	limbal stem cell allograft (eg, cadaveric or living donor)	18.14	18.40	18.40	1.34	37.88	37.88	090	
	65782	A	limbal conjunctival autograft (includes obtaining graft)	15.43	16.10	16.10	1.15	32.68	32.68	090	
•	65785		Implantation of intrastromal corneal ring segments	5.39	53.80	4.91	0.75	59.94	11.05	090	
	65800		Paracentesis of anterior chamber of eye (separate procedure); with removal of aqueous	1.53	1.74	0.96	0.11	3.38	2.60	000	
	65810	A	with removal of vitreous and/or discission of anterior hyaloid membrane, with or without air injection	5.82	6.97	6.97	0.43	13.22	13.22	090	
	65815	A	with removal of blood, with or without irrigation and/or air injection	6.00	11.64	7.12	0.44	18.08	13.56	090	
63	65820		Goniotomy	8.91	11.69	11.69	0.65	21.25	21.25	090	
	65850		Trabeculotomy ab externo	11.39	11.61	11.61	0.84	23.84	23.84	090	
A	65855		Trabeculoplasty by laser surgery	2.66	4.88	3.95	0.19	7.73	6.80	010	
	65860		Severing adhesions of anterior segment, laser technique (separate procedure)	3.59	4.90	3.34	0.26	8.75	7.19	090	
	65865	А	Severing adhesions of anterior segment of eye, incisional technique (with or without injection of air or liquid) (separate procedure); goniosynechiae	5.77	7.23	7.23	0.42	13.42	13.42	090	
	65870	A	anterior synechiae, except goniosynechiae	7.39	8.85	8.85	0.54	16.78	16.78	090	
	65875	A	posterior synechiae	7.81	9.51	9.51	0.57	17.89	17.89	090	
	65880	A	corneovitreal adhesions	8.36	9.82	9.82	0.62	18.80	18.80	090	
	65900		Removal of epithelial downgrowth, anterior chamber of eye	12.51	13.82	13.82	0.91	27.24	27.24	090	
	65920		Removal of implanted material, anterior segment of eye	9.99	11.67	11.67	0.74	22.40	22.40	090	
	65930		Removal of blood clot, anterior segment of eye	8.39	9.10	9.10	0.61	18.10	18.10	090	
	66020	A	Injection, anterior chamber of eye (separate procedure); air or liquid	1.64	3.52	1.98	0.12	5.28	3.74	010	
	66030	A	medication	1.30	3.29	1.75	0.10	4.69	3.15	010	

Code	M S	Description	Work Value	Non- Fac PE	Fac PE	Mal- practice	Non-Fac Total	Fac Total	Global (
88166	Х	with manual screening and computer-assisted	0.00	0.40	0.40	0.00	0.40	0.40	XXX
	26 TC	rescreening under physician supervision	$0.00 \\ 0.00$	$0.00 \\ 0.40$	$0.00 \\ 0.40$	$0.00 \\ 0.00$	$0.00 \\ 0.40$	$0.00 \\ 0.40$	XXX XXX
88167	X	with manual screening and computer-assisted	0.00	0.40	0.40	0.00	0.40	0.40	XXX
	26	rescreening using cell selection and review	0.00	0.00	0.00	0.00	0.00	0.00	XXX
00150	TC	under physician supervision	0.00	0.40	0.40	0.00	0.40	0.40	XXX
88172	26 A	Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine	0.69 0.69	0.90 0.35	0.90 0.35	0.03 0.02	1.62 1.06	1.62 1.06	XXX XXX
	TC A		0.00	0.55	0.55	0.01	0.56	0.56	XXX
88173	Α	interpretation and report	1.39	2.90	2.90	0.05	4.34	4.34	XXX
	26 A		1.39	0.65	0.65	0.03	2.07	2.07	XXX
	TC A		0.00	2.25	2.25	0.02	2.27	2.27	XXX
88174	X	7 1 07 0 1 0	0.00	0.81	0.81	0.00	0.81	0.81	XXX
	26 TC	system), collected in preservative fluid, automated thin layer preparation; screening by automated	$0.00 \\ 0.00$	0.00 0.81	0.00 0.81	$0.00 \\ 0.00$	0.00 0.81	$0.00 \\ 0.81$	XXX XXX
		system, under physician supervision							
88175	X	0 1	0.00	1.01	1.01	0.00	1.01	1.01	XXX
	26 TC	manual rescreening or review, under physician supervision	0.00 0.00	0.00	0.00	$0.00 \\ 0.00$	0.00 1.01	0.00 1.01	XXX XXX
88177	A		0.42	0.42	0.42	0.00	0.85	0.85	ZZZ
001//	26 A		0.42	0.21	0.21	0.01	0.64	0.64	ZZZ
		adequacy for diagnosis, each separate additional	0.00	0.21	0.21	0.00	0.21	0.21	ZZZ
		evaluation episode, same site (List separately in				·			
88182	A	addition to code for primary procedure) Flow cytometry, cell cycle or DNA analysis	0.77	2.36	2.36	0.04	3.17	3.17	XXX
00102	26 A		0.77	0.27	0.27	0.04	1.05	1.05	XXX
	TC A		0.00	2.09	2.09	0.03	2.12	2.12	XXX
88184	A	Flow cytometry, cell surface, cytoplasmic, or	0.00	2.12	2.12	0.01	2.13	2.13	XXX
	26	nuclear marker, technical component only; first	0.00	0.00	0.00	0.00	0.00	0.00	XXX
22125	TC	marker	0.00	2.12	2.12	0.01	2.13	2.13	XXX
88185	26 A	each additional marker (List separately in addition to code for first marker)	$0.00 \\ 0.00$	1.29 0.00	1.29 0.00	$0.00 \\ 0.00$	1.29 0.00	1.29 0.00	ZZZ ZZZ
	TC	addition to code for first marker)	0.00	1.29	1.29	0.00	1.29	1.29	ZZZ
88187	A	Flow cytometry, interpretation; 2 to 8 markers	1.36	0.61	0.61	0.07	2.04	2.04	XXX
88188	A		1.69	0.81	0.81	0.09	2.59	2.59	XXX
88189	Α	16 or more markers	2.23	0.86	0.86	0.10	3.19	3.19	XXX
88199		Unlisted cytopathology procedure	0.00	0.00	0.00	0.00	0.00	0.00	XXX
	26 C		0.00	0.00	0.00	0.00	0.00	0.00	XXX
	TC C		0.00	0.00	0.00	0.00	0.00	0.00	XXX
88230	26 X	Tissue culture for non-neoplastic disorders; lymphocyte	$0.00 \\ 0.00$	4.43 0.00	4.43 0.00	$0.00 \\ 0.00$	4.43 0.00	4.43 0.00	XXX XXX
	TC	lymphocyte	0.00	4.43	4.43	0.00	4.43	4.43	XXX
88233	X	skin or other solid tissue biopsy	0.00	5.35	5.35	0.00	5.35	5.35	XXX
	26		0.00	0.00	0.00	0.00	0.00	0.00	XXX
	TC		0.00	5.35	5.35	0.00	5.35	5.35	XXX
88235	X	amniotic fluid or chorionic villus cells	0.00	5.60	5.60	0.00	5.60	5.60	XXX
	26 TC		$0.00 \\ 0.00$	0.00 5.60	0.00 5.60	$0.00 \\ 0.00$	0.00 5.60	0.00 5.60	XXX XXX
88237		Tissue culture for neoplastic disorders; bone	0.00	4.80	4.80	0.00	4.80	4.80	XXX
0023/	26	marrow, blood cells	0.00	0.00	0.00	0.00	0.00	0.00	XXX
	TC		0.00	4.80	4.80	0.00	4.80	4.80	XXX
	X	solid tumor	0.00	5.61	5.61	0.00	5.61	5.61	XXX
88239	26		$0.00 \\ 0.00$	0.00	0.00	0.00	0.00	0.00	XXX
88239	TC		(1(1(1	5.61	5.61	0.00	5.61	5.61	XXX
	TC								
88239 88240	TC X 26	Cryopreservation, freezing and storage of cells, each cell line	0.00 0.00 0.00	0.38 0.00	0.38	0.00	0.38 0.00	0.38 0.00	XXX XXX